



# Healthcare-Associated Infections: Moving Toward Elimination

**Alice Guh, MD, MPH**

Division of Healthcare Quality Promotion  
Centers for Disease Control and Prevention

November 19, 2010

## **Elimination of Infectious Diseases**


**Maximal reduction of “the incidence of infection caused by a specific agent in a defined geographical area as a result of deliberate efforts; continued measures to prevent reestablishment of transmission are required.”**

# **LOCAL AND NATIONAL SUCCESSES**

# Examples of Local Successes: Implementation of CDC Guidelines

## Pittsburgh Regional Healthcare Initiative

FIGURE. Central line–associated bloodstream infection rate\* in 66 intensive care units (ICUs), by ICU type and semiannual period — southwestern Pennsylvania, April 2001–March 2005




\* Pooled mean rate per 1,000 central line days.

<sup>†</sup> Includes cardiothoracic, coronary, surgical, neurosurgical, trauma, medical, burn, and pediatric ICUs.

<sup>§</sup>  $p < 0.001$ .

Muto C et al. *MMWR* 2005;54:1013-6.


## Michigan Keystone Initiative



Pronovost P et al. *New Engl J Med* 2006;335:2725-32.

# Trends in Bloodstream Infections by ICU types, NHSN Hospitals, 1997–2007

**Figure 2.** Trends in Incidence of *Staphylococcus aureus* Central Line–Associated Bloodstream Infections by Intensive Care Unit Type—National Nosocomial Infections Surveillance System, 1997–2004; National Healthcare Safety Network, 2006–2007



- 2001 onward: MRSA CLABSIs decreased in all 6 ICU types: -51.5% to -69.2% relative change

Estimated:

- 7,000 BSIs prevented
- 1,800 lives saved
- \$50-\$180M in costs averted annually

# ABCs Surveillance: Healthcare-Associated Invasive MRSA Infections, 2005–2008

**Table 3.** Modeled Yearly Percent Change for All Invasive Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infections and Bloodstream Infections, January 2005-December 2008

Epidemiological Category	Modeled Yearly Percent Change (95% Confidence Intervals), % <sup>a</sup>	P Value
All invasive MRSA infections		
Hospital-onset	−9.4 (−14.7 to −3.8)	.005
Health care–associated community-onset	−5.7 (−9.7 to −1.6)	.01
MRSA bloodstream infections		
Hospital-onset	−11.2 (−15.9 to −6.3)	.001
Health care–associated community-onset	−6.6 (−9.5 to −3.7)	<.001
Dialysis in last year	−6.4 (−11.4 to −1.1) <sup>b</sup>	.02
No dialysis in last year	−7.2 (−11.4 to −2.8) <sup>b</sup>	.006

<sup>a</sup>Multilevel model adjusted for age and race unless otherwise specified.

<sup>b</sup>Unadjusted multilevel model.

**CURRENT STATE OF KNOWLEDGE**

# **HICPAC/CDC Guideline Development Process**

- ❑ Extensive systematic reviews of the medical literature**
- ❑ Recommendations graded according to evidence basis**
  - Generally supported by high-quality evidence
  - Some by indirect evidence or expert consensus
- ❑ Close collaboration with professional organizations (IDSA / SHEA)**

## Example of Evidence-Based Practice: Effect of Hand Hygiene on Resistant Organisms

Year	Author	Setting	Results
1982	Maki	Adult ICU	Reduction in infection rates
1984	Massanari	Adult ICU	Reduction in infection rates
1994	Webster	NICU	Elimination of MRSA
1995	Zafar	Newborn nursery	Elimination of MRSA
2000	Pittet	Hospitalwide	Reduction in infections and MRSA cross-transmission rates

Source: Guideline for Hand Hygiene in Health-care Settings. MMWR 2002;51(RR-16)

# HICPAC/CDC Evidence-Based Prevention Recommendations

- ❑ **Developed for each type of infection**
  - Prevention of central-line associated bloodstream infections (CLABSI)
  - Prevention of catheter associated urinary tract infections (CAUTI)
  - Prevention of surgical site infections (SSI)
  - Prevention of healthcare-associated pneumonia
  - Management of multi-drug resistant organisms
- ❑ **Guidelines contain many recommendations**

# Development of Toolkits for HAI Prevention

- ❑ Distilled current recommendations for optimal prevention strategies
  - Core Strategies
    - High levels of scientific evidence
    - Demonstrated feasibility
  - Supplemental Strategies
    - Some scientific evidence
    - Variable levels of feasibility

# HAI Prevention Toolkits

<http://www.cdc.gov/HAI/recoveryact/stateResources/toolkits.html>

## Toolkits

### Toolkits

Collaboration Primer: Establishing HAI Prevention Collaboratives using Recovery Act Funds

Collaboration Primer  [PPT - 920 KB]  
available in PowerPoint format.

### CAUTI

Catheter-associated Urinary Tract Infection (CAUTI) Toolkit  [PDF - 1.04 MB]

CAUTI Toolkit  [PPT - 996 KB]  
available in PowerPoint format

Activity C: ELC Prevention Collaboratives

CAUTI Baseline Prevention Practices Assessment Tool For States Establishing HAI Prevention Collaboratives Using Recovery Act Funds  [PDF - 229 KB]

### CDI

*Clostridium difficile* (CDI) Infections Toolkit  [PDF - 1.04 MB]

CDI Toolkit  [PPT - 4.34 MB]  
available in PowerPoint format

Activity C: ELC Prevention Collaboratives

*Clostridium Difficile* Infection (CDI) Baseline Prevention Practices Assessment Tool For States Establishing HAI Prevention Collaboratives Using ARRA Funds Recovery Act Funds  [PDF - 241 KB]

### CLABSI

Central Line-associated Bloodstream Infections (CLABSI) in Non-Intensive Care Unit (non-ICU) Settings Toolkit  [PDF - 508 KB]

CLABSI in non-ICU Settings  [PPT - 751 KB]  
available in PowerPoint format

Activity C: ELC Prevention Collaboratives

### Evaluating Environmental Cleaning

Options for Evaluating Environmental Cleaning

Available for download  [PDF - 333 KB]

Appendices to the Conceptual Program Model for Environmental Evaluation

CDC Environmental Checklist for Monitoring Terminal Cleaning  [PDF - 1.04 MB]

CDC Environmental Checklist  [Word - 52 KB]

Environmental Cleaning Eval Worksheet  [Excel - 63 KB]

### Long Term Care

Long Term Care baseline Prevention Practices Assessment Tool For States Establishing HAI Prevention Collaboratives Using Recovery Act Funds  [PDF - 1.04 MB]

Long Term Care Assessment Tool  [Word - 205 KB]  
available in Word format.

Inter-facility Infection Control Transfer Form  [PDF - 176]

Inter-facility Infection Control Transfer Form  [Word - 74]  
available in Word format.

### MRSA

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections  [PDF - 1.04 MB]

MRSA Toolkit  [PPT - 744 KB]  
available in PowerPoint format  
Activity C: ELC Prevention Collaboratives

MRSA Baseline Prevention Practices Assessment Tool For States Establishing HAI Prevention Collaboratives Using Recovery Act Funds  [PDF - 229 KB]

### SSI

Surgical Site Infection (SSI) Toolkit  [PDF - 208 KB]

SSI Toolkit  [PPT - 468 KB]  
available in PowerPoint format

Activity C: ELC Prevention Collaboratives

# Example of MDRO-Specific Guidance: Surveillance and Infection Prevention Measures



[CDC Home](#)

[Search](#)

[Health Topics A-Z](#)

## MMWR™

Weekly

March 20, 2009 / 58(10);256-260

## Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing *Enterobacteriaceae* in Acute Care Facilities

Infection with carbapenem-resistant *Enterobacteriaceae* (CRE) or carbapenemase-producing *Enterobacteriaceae* is emerging as an important challenge in health-care settings (1). Currently, carbapenem-resistant *Klebsiella pneumoniae* (CRKP) is the species of CRE most commonly encountered in the United States. CRKP is resistant to almost all available antimicrobial agents, and infections with CRKP have been associated with high rates of morbidity and mortality, particularly among persons with prolonged hospitalization and those who are critically ill and exposed to invasive devices (e.g., ventilators or central venous catheters). This report provides updated recommendations from CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC) for the control of CRE or carbapenemase-producing *Enterobacteriaceae* in acute care (inpatient) facilities. For all acute care facilities, CDC and HICPAC recommend an aggressive infection control strategy, including managing all patients with CRE using contact precautions and implementing Clinical and Laboratory Standards Institute (CLSI) guidelines for detection of carbapenemase production. In areas where CRE are not endemic, acute care facilities should 1) review microbiology records for the preceding 6--12 months to determine whether CRE have been recovered at the facility, 2) if the review finds previously unrecognized CRE, perform a point

## **Current State of Affairs: Suboptimal Adherence to Proven Practices**

- ❑ Average hand hygiene compliance: ~40%**
- ❑ Compliance with timing of surgical prophylaxis: ~40%**
- ❑ Full compliance with key guidelines to prevent HAIs: 30%-38% of U.S. hospitals**
- ❑ Continued outbreaks due to inattention to basic infection control**
- ❑ CDC guidelines not always part of federal standards/regulations**

# **IMPROVING ADHERENCE TO EVIDENCE-BASED PRACTICES**

# Collaborative and Integrated Approach

- ❑ Targeted education
- ❑ Alignment of incentives
- ❑ Partnerships and collaborations

# Collaborative and Integrated Approach

- ❑ Targeted education
- ❑ Alignment of incentives
- ❑ Partnerships and collaborations

# Educational Intervention to Improve Environmental Cleaning (I)



## Study Design (n=36 hospitals)

- ❑ **Pre-intervention: 48% cleaning rate of a sample of 14 different types of high-risk contact surfaces**
  - Lowest mean cleaning rates (22–29%): bathroom door knobs, handhold, light switch; room door knobs; bedpan cleaner
- ❑ **Phase II: standardized educational presentation**
- ❑ **Phase III: Performance feedback, additional interventions (programmatic)**

# Educational Intervention to Improve Environmental Cleaning (II)

## Results

- Change in mean rate of cleaning over study period
- High-risk contact surfaces with lowest baseline rates: pre- vs post-intervention



# Targeted Educational Initiative to Improve Injection Practices

## ❑ Safe Injection Practices Coalition

<http://www.oneandonlycampaign.org/>

The screenshot shows the homepage of the One & Only Campaign website. At the top, there is a navigation bar with six teal buttons: "ABOUT THE CAMPAIGN", "LEARN ABOUT SAFE INJECTION PRACTICES", "HEALTHCARE PROVIDER INFORMATION", "PATIENT INFORMATION", "MEDIA & EVENTS", and "CONTACT US". Below the navigation bar is a large banner featuring a group of diverse healthcare professionals in scrubs. On the left side of the banner, there is a graphic with a large teal number "1" and the text "ONE NEEDLE, ONE SYRINGE, ONLY ONE TIME." Below this is an image of a syringe and the text "Safe Injection Practices Coalition www.ONEandONLYcampaign.org".

*The One & Only Campaign is a public health campaign aimed at raising awareness among the general public and healthcare providers about safe injection practices.*

[Learn More About Our Pilot Sites](#)

**EVENTS**  
[One & Only Campaign Website Launch](#)

**NEWS**  
[Jury awards Henderson couple a record \\$500 million award](#)

[SAFE INJECTION PRACTICES VIDEO](#)

# One & Only Campaign Materials

## □ Pilot state campaigns: Nevada, New York

### A Patient Safety Threat - Syringe Reuse

(Source: Division of Healthcare Quality Promotion (DHQP), Centers for Disease Control and Prevention (CDC), February 2008)



Healthcare providers (doctors, nurses, and anyone providing injections) should **never reuse a needle or syringe**. Use one needle for only one patient. Never put a used needle into a shared vial. Both needle and syringe must be discarded. It is also never safe to change the needle and reuse the syringe - this practice can transmit disease.

**A single-use vial** is a bottle of liquid medication that is administered to a patient by injection of infusion (e.g., using a needle and syringe). Single-use vials should only be used for one patient, for one procedure, using a new, clean needle and new, clean syringe. Any medication remaining in the vial at the end of the procedure **must** be discarded and may not be used on additional patients.



**A multi-dose vial** is a bottle of liquid medication that contains more than one dose of medication and is approved by the Food and Drug Administration (FDA) for use on multiple persons. A new, clean needle and syringe should always be used to access the medication in a multi-dose vial. The reuse of needles or syringes to access multi-dose vial medication can result in contamination of the medicine with microbes that can be spread to others when the medicine is used again.

The CDC recommends that single-use vials be used whenever possible and that multi-dose vials of medication be assigned to a single patient to reduce the risk of disease transmission.

Reusing a needle or syringe puts patients in danger of getting hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV. When it is discovered that reuse of a needle or syringe has occurred, patients who may have been affected should be notified.

Healthcare providers should always adhere to **Safe Injection Practices** under **Standard Precautions** to prevent disease transmission from needles, syringes, or vials of medication.

### About the Safe Injection Practices Coalition

The Safe Injection Practices Coalition was established in 2008. The following organizations are members of the Coalition: Accreditation Association for Ambulatory Health Care (AAAHC), American Association of Nurse Anesthetists (AANA), Ambulatory Surgery Foundation, Association for Professionals in Infection Control and Epidemiology, Inc (APIC), BD (Becton, Dickinson and Company), Centers for Disease Control and Prevention (CDC), CDC Foundation, Covidien, HONOReform Foundation, Hospira, National Association of County & City Health Officials (NACCHO), Nebraska Medical Association (NMA), Nevada State Medical Association (NSMA) and Premier Safety Institute.



For more information, please visit our website at: [www.ONEandONLYcampaign.org](http://www.ONEandONLYcampaign.org)

### A Patient Safety Threat – Syringe Reuse

(Source: Division of Healthcare Quality Promotion (DHQP), Centers for Disease Control and Prevention (CDC), February 2008)

Healthcare providers (doctors, nurses, and anyone providing



### Injection Safety: What Healthcare Providers Need to Know

[www.ONEandONLYcampaign.org](http://www.ONEandONLYcampaign.org)

### About the Safe Injection Practices Coalition

The Safe Injection Practices Coalition was established in 2008.

The following organizations are members of the Coalition: Accreditation Association for Ambulatory Health Care (AAAHC), American Association of Nurse Anesthetists (AANA), Ambulatory Surgery Foundation, Association for Professionals in Infection Control and Epidemiology, Inc (APIC), BD (Becton, Dickinson and Company), Centers for Disease Control and Prevention (CDC), CDC Foundation, Covidien, HONOReform Foundation, Hospira, National Association of County & City Health Officials (NACCHO), Nebraska Medical Association (NMA), Nevada State Medical Association (NSMA) and Premier Safety Institute.



For more information, please visit our website at: [www.ONEandONLYcampaign.org](http://www.ONEandONLYcampaign.org)

### Some Things Should Never Be Reused



### A Patient's Guide to Injection Safety

[www.ONEandONLYcampaign.org](http://www.ONEandONLYcampaign.org)

# Collaborative and Integrated Approach

- ❑ Targeted education
- ❑ Alignment of incentives
- ❑ Partnerships and collaborations

## **Promote System-Wide Improvement**

- ❑ **Create sustainable HAI elimination**
  - Healthcare payment incentives
  - Oversight and accreditation
- ❑ **Encourage systems of care that are prevention oriented**
- ❑ **Prevention of HAIs embedded in processes of care**

# Centers for Medicare and Medicaid Services (CMS)

- ❑ **October 2008**
- ❑ **Non-payment rules for “Never events”**
  - Preventable conditions acquired during patient’s hospital stay
  - Includes HAI bloodstream infections, urinary tract infections, and selected surgical site infections

# Federal Efforts to Improve Oversight and Enforcement

- ❑ **Strengthen regulatory and accreditation standards across all healthcare settings**
  - Particular focus on infection control
- ❑ **Collaboration with CMS**
  - Expanded incorporation of infection control requirements into conditions for coverage and inspection procedures
    - Hemodialysis
    - Ambulatory surgical centers

# ASC Infection Control Survey Tool

## PART 2 – INFECTION CONTROL & RELATED PRACTICES

### Instructions:

- Circle the applicable response, as well as information on the manner in which information was obtained
- Unless otherwise indicated, a “No” response to any question below must be cited as a deficient practice in relation to 42 CFR 416.51(a).
- If N/A is circled, please explain why there is no associated observation, or why the question is not applicable

### I. Hand Hygiene

#### Additional Instructions:

- **Observations are to focus on staff directly involved in patient care (e.g., physicians, nurses, CRNAs, etc.).** Hand hygiene should be observed not only during t while making other observations in the ASC throughout the survey. provide additional evidence for what the surveyor has observed, bu



[http://www.cms.hhs.gov/SurveyCertificationGenInfo/downloads/SCLetter09\\_37.pdf](http://www.cms.hhs.gov/SurveyCertificationGenInfo/downloads/SCLetter09_37.pdf)

## **State Efforts to Improve Oversight and Enforcement**

- ❑ Periodic infection control training requirements for licensed healthcare providers (NY)**
- ❑ Requirement for outpatient endoscopy and surgical centers to retain a licensed Infection Preventionist (NJ)**
- ❑ Increased licensing, accreditation, and/or inspection requirements for physician offices and clinics based on levels of anesthesia or sedation provided (NY, NV)**

# Collaborative and Integrated Approach


- ❑ Targeted education
- ❑ Alignment of incentives
- ❑ Partnerships and collaborations

## Importance of Teamwork

- ❑ Collaboration across all healthcare personnel groups
- ❑ Each person has role in HAI prevention
- ❑ Empowered to promote patient safety
  - Success of positive deviance programs

**“Collaboration rather than competition should be the hallmark of elimination efforts.”**

# Increasing Needs and Opportunities for Partnerships Across the Continuum of Care



# Regional Approach May be the Key

CONTROL OF VANCOMYCIN-RESISTANT ENTEROCOCCUS IN HEALTH CARE FACILITIES IN A REGION

---

## CONTROL OF VANCOMYCIN-RESISTANT ENTEROCOCCUS IN HEALTH CARE FACILITIES IN A REGION

BELINDA E. OSTROWSKY, M.D., M.P.H., WILLIAM E. TRICK, M.D., ANNETTE H. SOHN, M.D., STEPHEN B. QUIRK, M.P.P., STACEY HOLT, M.M.Sc., LORETTA A. CARSON, M.S., BERTHA C. HILL, B.S., MATTHEW J. ARDUINO, Ph.D., MATTHEW J. KUEHNERT, M.D., AND WILLIAM R. JARVIS, M.D.

- ❑ Emergence of VRE in acute care facilities and LTCF in Siouxland region
- ❑ Collaboration among health departments and all 32 facilities controlled VRE outbreak

## **A New Model for Prevention: Prevention Collaboratives**

- ❑ Gold standard in HAI prevention**
- ❑ Group of healthcare facilities engaged in a common effort to reduce HAIs**
- ❑ Members use a common strategy**
- ❑ Discuss progress regularly and share lessons learned in real time**

## **Strengths of a Prevention Collaborative**

- ❑ Opportunities to share experiences on what works and does not work**
- ❑ Ability to get advice from others who are working on the same project**
- ❑ Peer pressure is also a motivator**
- ❑ Regional prevention collaborative is key in preventing MDRO transmission**

# What's the Minimum Size of a Prevention Collaborative?

- ❑ **2 or more facilities working together meaningfully**
- ❑ **Ideal size depends on multiple factors**
  - Specific subject or targeted HAI
  - Type of healthcare facilities
  - Available resources
  - More “cutting edge” — smaller number
  - More established “change packages” can be quite large
  - Level of enthusiasm

# Lessons Learned from Pittsburgh and Michigan

- ❑ **Successful collaboration among participating hospitals with varying ICU types**
- ❑ **Prevention practices utilized during these interventions were not novel**
- ❑ **Practical implementation strategies identified that can be successful across many facilities**

# Common Elements for Successful Infection Prevention

- ❑ Simple
- ❑ Patient-centered, integrated with care
- ❑ Evidence-based recommendations
- ❑ Part of a “package” for prevention
- ❑ Engaging and empowering providers
- ❑ Protocols and systems in place
- ❑ Standardized ways for recording information about infections (e.g., NHSN)
- ❑ Regular feedback of information to providers
- ❑ Changing to a pro-safety culture
- ❑ Leadership support

# State-Based HAI Prevention Collaboratives

- ❑ **ARRA funded collaboratives (fully or in part) – July 2010**
- ❑ **39 states, 45 collaboratives**
  - CLABSI (n=14)
  - CAUTI (n=5)
  - MRSA (n=9)
  - SSI (n=6)
- ❑ **Vermont: MDRO prevention collaborative involving all acute care facilities + LTCFs**

# **ADDRESSING GAPS IN KNOWLEDGE**

## Improving HAI Surveillance

- ❑ **Provide accurate and timely data to assess HAI risks and impact of prevention strategies**
- ❑ **Continue refining and developing new standard definitions and surveillance methods**
  - Capture nonhospital HAIs
- ❑ **Identify less-labor intensive method**
  - Algorithmic detection of HAIs
  - Capture through electronic health information records

# Building Capacity for Outbreak Response

- ❑ Investigations of HAIs or adverse events in various healthcare settings
- ❑ Why we care so much about outbreaks
  - Major detriment to patient care and safety
  - Possible massive financial and public health impacts (e.g. undermine preventive care)
  - Sentinel events and can play a major role in making recommendations that improve overall patient care
  - Provide important opportunities for education

## Continuing Prevention Research

- ❑ **Develop effective prevention strategies**
  - Particularly non-ICU and nonhospital settings
- ❑ **Enhance understanding of the epidemiology of certain HAI pathogens**
- ❑ **Identify strategies for improving adherence**

***Infection Prevention is  
Everyone's Responsibility!***



# Thank you

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: [cdcinfo@cdc.gov](mailto:cdcinfo@cdc.gov) Web: [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

National Center for Emerging and Zoonotic Infectious Diseases  
Division of Healthcare Quality Promotion

